ethyl 4-[(4-methoxybenzenesulfonyl)pyridin-3-ylmethylamino]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate | 206258-87-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: ethyl 4-[(4-methoxybenzenesulfonyl)pyridin-3-ylmethylamino]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate
• 英文别名: ethyl 4-[(4-methoxyphenyl)sulfonyl-(pyridin-3-ylmethyl)amino]-1-phenylpyrazolo[3,4-b]pyridine-5-carboxylate
• CAS: 206258-87-9
• 化学式: C₂₈H₂₅N₅O₅S
• 分子量: 543.603
• InChiKey: NGLUKYPNWRHFHT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  39
• 可旋转键数：
  10
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  125
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  ethyl 4-[(4-methoxybenzenesulfonyl)pyridin-3-ylmethylamino]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 在 sodium hydroxide 作用下， 生成 4-[(4-methoxybenzenesulfonyl)pyridin-3-ylmethylamino]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid
  参考文献：
  名称：

  Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors

  摘要：

  Potent and selective bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors were synthesized by a novel convergent route. Selectivity and efficacy versus MMPs and TACE could be controlled by appropriate substitution on the scaffolds and by variation of the P1' group. Select compounds were found to be effective in in vivo models of arthritis. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00127-6
• 作为产物：
  描述：

  4-oxo-1-phenyl-4,7-dihydro-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl ester 在 sodium hydride 、 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 ethyl 4-[(4-methoxybenzenesulfonyl)pyridin-3-ylmethylamino]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate
  参考文献：
  名称：

  Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors

  摘要：

  Potent and selective bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors were synthesized by a novel convergent route. Selectivity and efficacy versus MMPs and TACE could be controlled by appropriate substitution on the scaffolds and by variation of the P1' group. Select compounds were found to be effective in in vivo models of arthritis. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00127-6

文献信息

• Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors
  申请人：American Cyanamid Company

  公开号：US06228869B1

  公开（公告）日：2001-05-08

  This invention provides, low molecular weight, non-peptide inhibitors of matrix metalloproteinases and TNF-&agr; converting enzyme (TACE, tumor necrosis factor-&agr; converting enzyme) of formula: B wherein B is P and Q are provided that when P is Q is and vice versa; or a pharmaceutically acceptable salt thereof.

  这项发明提供了一种低分子量、非肽类的基质金属蛋白酶和TNF-α转化酶（TACE，肿瘤坏死因子-α转化酶）的抑制剂，其化学式为：B其中B是P和Q，当P为时，Q为，反之亦然；或其药用盐。
• Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
  申请人：American Cyanamid Company

  公开号：US20030208066A1

  公开（公告）日：2003-11-06

  Compounds of the formula 1 which are useful in disease conditions mediated by TNF-&agr;, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.

  式1的化合物在由TNF-α介导的疾病条件中很有用，如类风湿关节炎、骨关节炎、败血症、艾滋病、溃疡性结肠炎、多发性硬化症、克罗恩病和软骨退行性损失。
• Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
  申请人：——

  公开号：US20010025047A1

  公开（公告）日：2001-09-27

  This invention provides, low molecular weight, non-peptide inhibitors of matrix metalloproteinases and TNF-&agr; converting enzyme (TACE, tumor necrosis factor-&agr; converting enzyme) of formula: B wherein B is 1 P and Q are 2 provided that when P is 3 and vice versa; T, U, W, and X are each, independently, carbon or nitrogen, provided that when T or U is carbon, either may be optionally substituted with R 1 ; Y is carbon, nitrogen, oxygen or sulfur, provided that at least one of T, U, W, X, and Y is not carbon, and further provided that no more than 2 of T, U, W, and X are nitrogen; 4 is a phenyl ring or is a heteroaryl ring of ring 5-6 atoms which may contain 0-2 heteratoms selected from nitrogen, oxygen, and sulfur, in addition to any heteroatoms defined by W or X; wherein the phenyl or heteroaryl ring may be optionally mono-, di-, or tri-substituted with R 1 ; Z is a phenyl, naphthyl, heteroaryl, or heteroaryl fused to phenyl, wherein the heteroaryl moiety contains of 5-6 ring atoms and 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur; wherein the phenyl, naphthyl, heteroaryl, or phenyl fused heteroaryl moieties may be optionally mono-, di-, or tri-substituted with R 1 ; R 1 is hydrogen, halogen, alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cyclocalkyl of 3-6 carbon atoms, —(CH 2 ) n Z, —OR 2 , —CN, —COR 2 , perfluoroalkyl of 1-4 carbon atoms, —CONR 2 R 3 , —S(O) X R 2 —OPO(OR 2 )OR 3 , —PO(OR 2 )R 3 , —OC(O)NR 2 R 3 , —COOR 2 , —CONR 2 R 3 , —SO 3 H, —NR 2 R 3 , —NR 2 COR 3 , —NR 2 COOR 3 , —SO 2 NR 2 R 3 , —NO 2 , —N(R 2 )SO 2 R 3 , —NR 2 CONR 2 R 3 ,—NR 2 C(═NR 3 )NR 2 R 3 , —SO 2 NHCOR 4 , —CONHSO 2 R 4 , -tetrazol-5-yl, —SO 2 NHCN, —SO 2 NHCONR 2 R 3 , or Z; V is a saturated or partially unsaturated heterocycloalkyl ring of 5-7 ring atoms having 1-3 heteroatoms selected from N, O, or S, which may be optionally mono-, or di-substituted with R 2 ; R 2 and R 3 are each, independently, hydrogen, alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 3-6 carbon atoms; perfluoroalkyl of 1-4 carbon atoms, Z or V; R 4 is alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 3-6 carbon atoms; perfluoroalkyl of 1-4 carbon atoms, Z or V; R 5 is hydrogen, alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, Z, or V; n=1-6; X=0-2 or a pharmaceutically acceptable salt thereof.

  该发明提供了低分子量、非肽类的基质金属蛋白酶和TNF-α转化酶（TACE，肿瘤坏死因子-α转化酶）抑制剂，其化学式为：B其中，B为1。P和Q为2，但当P为3时，反之亦然；T、U、W和X各自独立地为碳或氮，但当T或U为碳时，可以任选一个用R1取代；Y为碳、氮、氧或硫，但至少有一个T、U、W、X和Y不为碳，并且进一步提供不超过2个T、U、W和X为氮；4为苯环或环5-6原子的杂环环，除了由W或X定义的任何杂原子外，还可以包含0-2个从氮、氧和硫中选择的杂原子，其中苯环或杂环环可以选择性地单取代、二取代或三取代R1；Z为苯、萘、杂环或与苯融合的杂环，其中杂环基团包含5-6个环原子和1-3个从氮、氧或硫中选择的杂原子；其中苯、萘、杂环或苯融合的杂环基团可以选择性地单取代、二取代或三取代R1；R1为氢、卤素、1-8个碳原子的烷基、2-6个碳原子的烯基、2-6个碳原子的炔基、3-6个碳原子的环烷基、-(CH2)nZ、-OR2、-CN、-COR2、1-4个碳原子的全氟烷基、-CONR2R3、-S(O)XR2-OPO(OR2)OR3、-PO(OR2)R3、-OC(O)NR2R3、-COOR2、-CONR2R3、-SO3H、-NR2R3、-NR2COR3、-NR2COOR3、-SO2NR2R3、-NO2、-N(R2)SO2R3、-NR2CONR2R3、-NR2C(═NR3)NR2R3、-SO2NHCOR4、-CONHSO2R4、-四唑-5-基、-SO2NHCN、-SO2NHCONR2R3或Z；V为5-7个环原子的饱和或部分不饱和的杂环烷基环，其中有1-3个从N、O或S中选择的杂原子，可以选择性地单取代或二取代R2；R2和R3各自独立地为氢、1-8个碳原子的烷基、2-6个碳原子的烯基、2-6个碳原子的炔基、3-6个碳原子的环烷基、1-4个碳原子的全氟烷基、Z或V；R4为1-8个碳原子的烷基、2-6个碳原子的烯基、2-6个碳原子的炔基、3-6个碳原子的环烷基、1-4个碳原子的全氟烷基、Z或V；R5为氢、1-8个碳原子的烷基、2-6个碳原子的烯基、2-6个碳原子的炔基、Z或V；n为1-6；X为0-2或其药学上可接受的盐。
• Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
  申请人：——

  公开号：US20010046989A1

  公开（公告）日：2001-11-29

  This invention provides, low molecular weight, non-peptide inhibitors of matrix metalloproteinases and TNF-&agr; converting enzyme (TACE, tumor necrosis factor-&agr; converting enzyme) of formula: B wherein B is 1 2 T, U, W, and X are each, independently, carbon or nitrogen, provided that when T or U is carbon, either may be optionally substituted with R 1 ; Y is carbon, nitrogen, oxygen or sulfur, provided that at least one of T, U, W, X, and Y is not carbon, and further provided that no more than 2 of T, U, W, and X are nitrogen; 3 is a phenyl ring or is a heteroaryl ring of ring 5-6 atoms which may contain 0-2 heteratoms selected from nitrogen, oxygen, and sulfur, in addition to any heteroatoms defined by W or X; wherein the phenyl or heteroaryl ring may be optionally mono-, di-, or tri- substituted with R 1 ; Z is a phenyl, naphthyl, heteroaryl, or heteroaryl fused to phenyl, wherein the heteroaryl moiety contains of 5-6 ring atoms and 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur; wherein the phenyl, naphthyl, heteroaryl, or phenyl fused heteroaryl moieties may be optionally mono-, di-, or tri- substituted with R 1 ; R 1 is hydrogen, halogen, alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cyclocalkyl of 3-6 carbon atoms, —(CH 2 ) n Z, —OR 2 , —CN, —COR 2 , perfluoroalkyl of 1-4 carbon atoms, —CONR 2 R 3 , —S(O) x R 2 —OPO(OR 2 )OR 3 , —PO(OR 2 )R 3 , —OC(O)NR 2 R 3 , —COOR 2 , —CONR 2 R 3 , —SO 3 H, —NR 2 R 3 , —NR 2 COR 3 , —NR 2 COOR 3 , —SO 2 NR 2 R 3 , —NO 2 , —N(R 2 )SO 2 R 3 , —NR 2 CONR 2 R 3 , —NR 2 C(═NR 3 )NR 2 R 3 , —SO 2 NHCOR 4 , —CONHSO 2 R 4 , -tetrazol-5-yl, —SO 2 NHCN, —SO 2 NHCONR 2 R 3 or Z; V is a saturated or partially unsaturated heterocycloalkyl ring of 5-7 ring atoms having 1-3 heteroatoms selected from N, O, or S, which may be optionally mono-, or di-substituted with R 2 ; R 2 and R 3 are each, independently, hydrogen, alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 3-6 carbon atoms; perfluoroalkyl of 1-4 carbon atoms, Z or V; R 4 is alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 3-6 carbon atoms; perfluoroalkyl of 1-4 carbon atoms, Z or V; R 5 is hydrogen, alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, Z, or V; n=1-6; x=0-2 or a pharmaceutically acceptable salt thereof.

  本发明提供了低分子量、非肽类的矩阵金属蛋白酶和TNF-α转化酶（TACE，肿瘤坏死因子-α转化酶）抑制剂，其化学式为：B，其中B为12T、U、W和X，每个独立地为碳或氮，但当T或U为碳时，可以选择性地用R1进行取代；Y为碳、氮、氧或硫，但要求T、U、W、X和Y中至少有一个不为碳，且T、U、W和X中最多只有2个为氮；3为苯环或环5-6原子的杂环环，该环可能包含0-2个来自氮、氧和硫的杂原子，除了W或X定义的任何杂原子外；其中苯环或杂环环可以选择性地被R1单取代、双取代或三取代；Z为苯、萘、杂环或与苯融合的杂环，其中杂环基团包含5-6个环原子和1-3个来自氮、氧或硫的杂原子；其中苯、萘、杂环或融合苯的杂环基团可以选择性地被R1单取代、双取代或三取代；R1为氢、卤素、1-8个碳原子的烷基、2-6个碳原子的烯基、2-6个碳原子的炔基、3-6个碳原子的环烷基、-(CH2)nZ、-OR2、-CN、-COR2、1-4个碳原子的全氟烷基、-CONR2R3、-S(O)xR2-OPO(OR2)OR3、-PO(OR2)R3、-OC(O)NR2R3、-COOR2、-CONR2R3、-SO3H、-NR2R3、-NR2COR3、-NR2COOR3、-SO2NR2R3、-NO2、-N(R2)SO2R3、-NR2CONR2R3、-NR2C(═NR3)NR2R3、-SO2NHCOR4、-CONHSO2R4、-四唑-5-基、-SO2NHCN、-SO2NHCONR2R3或Z；V为5-7个环原子、1-3个来自N、O或S的杂原子的饱和或部分不饱和杂环烷基环，该环可能选择性地被R2单取代或双取代；R2和R3各自独立地为氢、1-8个碳原子的烷基、2-6个碳原子的烯基、2-6个碳原子的炔基、3-6个碳原子的环烷基、1-4个碳原子的全氟烷基、Z或V；R4为1-8个碳原子的烷基、2-6个碳原子的烯基、2-6个碳原子的炔基、3-6个碳原子的环烷基、1-4个碳原子的全氟烷基、Z或V；R5为氢、1-8个碳原子的烷基、2-6个碳原子的烯基、2-6个碳原子的炔基、Z或V；n为1-6；x为0-2或其药学上可接受的盐。
• Acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
  申请人：American Cyanamid Company

  公开号：EP1279674A2

  公开（公告）日：2003-01-29

  Compounds of the formula are provided wherein P and Q are or provided that when P is , Q is , and vice versa; which are useful in disease conditions mediated by TNF-α, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.

  式中的化合物 其中 P 和 Q 为 或 当 P 是 时，Q 为 反之亦然； 它们适用于由 TNF-α 介导的疾病，如类风湿性关节炎、骨关节炎、败血症、艾滋病、溃疡性结肠炎、多发性硬化症、克罗恩病和软骨退化。